Effectiveness of IL-12/23 inhibition (ustekinumab) versus tumour necrosis factor inhibition in psoriatic arthritis: observational PsABio study resultsJosef S Smolen, Stefan Siebert, Tatiana V Korotaeva, Carlo Selmi, Paul Bergmans, Elisa Gremese, Beatriz Joven-Ibáñez, Gkikas Katsifis, Wim Noël, Michael T Nurmohamed, Pascal Richette, Petros P Sfikakis, Kurt de Vlam, Elke Theander, Laure Gossec
12 October 2021
Efficacy and safety of tildrakizumab in patients with active psoriatic arthritis: results of a randomised, double-blind, placebo-controlled, multiple-dose, 52-week phase IIb studyPhilip J Mease, Saima Chohan, Ferran J Garcia Fructuoso, Michael E Luggen, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Alice Gottlieb
12 August 2021
Safety and efficacy of faecal microbiota transplantation for active peripheral psoriatic arthritis: an exploratory randomised placebo-controlled trialMaja Skov Kragsnaes, Jens Kjeldsen, Hans Christian Horn, Heidi Lausten Munk, Jens Kristian Pedersen, Søren Andreas Just, Palle Ahlquist, Finn Moeller Pedersen, Maarten de Wit, Sören Möller, Vibeke Andersen, Karsten Kristiansen, Dorte Kinggaard Holm, Hanne Marie Holt, Robin ChristensenSee the full list of authors
12 August 2021
IL-23 skin and joint profiling in psoriatic arthritis: novel perspectives in understanding clinical responses to IL-23 inhibitorsAlessandra Nerviani, Marie-Astrid Boutet, Wang Sin Gina Tan, Katriona Goldmann, Nirupam Purkayastha, Tamas Ajtos Lajtos, Rebecca Hands, Myles Lewis, Stephen Kelly, Costantino Pitzalis
12 April 2021
Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trialXenofon Baraliakos, Laure Gossec, Effie Pournara, Slawomir Jeka, Antonio Mera-Varela, Salvatore D'Angelo, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C Coates
12 April 2021
Upadacitinib for psoriatic arthritis refractory to biologics: SELECT-PsA 2Philip J Mease, Apinya Lertratanakul, Jaclyn K Anderson, Kim Papp, Filip Van den Bosch, Shigeyoshi Tsuji, Eva Dokoupilova, Mauro Keiserman, Xin Wang, Sheng Zhong, Reva M McCaskill, Patrick Zueger, Aileen L Pangan, William Tillett
11 February 2021
Brodalumab in psoriatic arthritis: results from the randomised phase III AMVISION-1 and AMVISION-2 trialsPhilip J Mease, Philip S Helliwell, Kasper Fjellhaugen Hjuler, Kyle Raymond, Iain McInnes
12 January 2021
Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation studyJiangwei Xia, Shu-Yang Xie, Ke-Qi Liu, Lin Xu, Pian-Pian Zhao, Si-Rui Gai, Peng-Lin Guan, Jin-Qiu Zhao, Yan-Ping Zhu, Lam C Tsoi, Philip E Stuart, Rajan P Nair, Han-Qi Yang, Yu-Ting Liao, Kaijing MaoSee the full list of authors
12 October 2020
Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52Josef S Smolen, Philip Mease, Hasan Tahir, Hendrik Schulze-Koops, Inmaculada de la Torre, Lingnan Li, Maja Hojnik, Christophe Sapin, Masato Okada, Roberto Caporali, Jordi Gratacós, Philippe Goupille, Soyi Liu Leage, Sreekumar Pillai, Peter Nash
14 September 2020
DAPSA, carotid plaque and cardiovascular events in psoriatic arthritis: a longitudinal studySteven Ho Man Lam, Isaac T Cheng, Edmund K Li, Priscilla Wong, Jolie Lee, Ronald Man-Lung Yip, Cheuk-Wan Yim, Shirley K Ying, Martin Li, Tena K Li, Alex Pui-Wai Lee, Lai-Shan Tam
14 September 2020
